There is a growing "Valley of Death" in funding for the development of new disease treatments. Investment is needed to turn promising discoveries into products. But fiscal realities are causing government, researchers, industry and venture capital funders of medical research to become increasingly conservative and risk-averse in their approaches to R&D and deal-making, despite the fact that the threat to pharmaceutical companies' pipelines has never been greater. The need for new financing models and return on medical research investment is acute. This panel will highlight some alternative and novel mechanisms for identifying and funding high-impact research that can deliver medical solutions to patients.
Executive Director, FasterCures / The Center for Accelerating Medical Solutions
Head, Therapeutics and Diagnostics Section, SBIR Development Center, National Cancer Institute
Managing Director and Global Head of Biopharmaceutical Equity Research, Credit Suisse
Lt. Colonel, USAF MC; Program Manager, Defense Advanced Research Projects Agency (DARPA), Defense Sciences Office